Cannabis may help lower pressure inside the eye. Here is why your ophthalmologist still won’t prescribe it.

Let’s start somewhere this series rarely gets to start. Cannabis works.

Cannabis has been shown to lower pressure inside the eye. Researchers measured it in glaucoma patients almost fifty years ago, reproduced it across smoked, swallowed and under-the-tongue routes, and no eye specialist disputes it today. If you arrived asking whether cannabis for glaucoma does anything at all, you were right.

This article covers why. The story of cannabis and glaucoma is not a plant being dismissed. It is a real finding running into a clock.

What Glaucoma Is Doing While You Read This

 

Glaucoma damages the optic nerve, the cable between your eye and your brain. Irreversible. That is the word doing the work, because sight lost to glaucoma never comes back, and it is why the whole of glaucoma care is about protecting what remains rather than recovering what is gone.

Pressure inside the eye is the one risk factor anybody can change, and the Early Manifest Glaucoma Trial showed what changing it buys. Two hundred and fifty-five patients, six years, pressure lowered by about a quarter. Vision loss still progressed in 45 percent of them. In the untreated group, 62 percent.

Better, and no cure. That gap is the honest size of the best lever medicine has, and it is the lever cannabis gets measured against.

Why Cannabis Lowers Eye Pressure

 

Your eye makes fluid and drains it continuously. Pressure inside the eye, what your ophthalmologist calls intraocular pressure, is the balance between this mechanism.

Cannabinoid receptors sit exactly where the balance gets struck: in the ciliary body, the fluid-making tissue, and in the trabecular meshwork and Schlemm’s canal, its drainage channels. THC acts at those receptors and can slow production and improve outflow. For an explanation on ho this signaling network operates throughout the body, our complete guide to the endocannabinoid system covers it properly.

There is a secondary mechanism. Cannabis lowers blood pressure everywhere, the ciliary body’s own blood supply included. Less pressure pushing fluid in, less fluid made.

Two routes to the same number. Only one of them is doing something you would want.

 

What the Evidence on Cannabis for Glaucoma Shows

 

In 1980, researchers published what happened when 18 glaucoma patients inhaled marijuana. Pressure fell. So did blood pressure, and so did a great deal else. All 18 experienced some alteration in sensorium, from hunger and thirst to drowsiness and euphoria. Eight had anxiety with a racing heart and palpitations. Five had postural hypotension, one a regular user of five or six years’ standing. Experience did not protect him.

The authors did not bury their conclusion. Those effects occurred, they wrote, with such frequency as to weigh against routine use in the general glaucoma population. Then they said what should happen next. Find a way to deliver the compound locally, to the eye itself.

Forty-four years later, a 2024 review in Medical Cannabis and Cannabinoids went looking for what had come of it. Two databases, 293 papers after duplicates, seven human clinical studies from the whole of this century. Seven. The review’s four key messages are worth reading exactly as written: “Cannabinoids lower intraocular pressure. However, the effect is short-lived. There is also a lack of well-formulated ocular delivery system. The available evidence is inadequate to recommend the use of cannabinoids for the routine treatment of glaucoma.”

The professional bodies got there earlier and have not moved. The American Glaucoma Society published “Marijuana and the Treatment of Glaucoma” in 2010 and a pediatric statement in 2019. The Brazilian Glaucoma Society titled its 2021 statement “Marijuana for glaucoma treatment: a recipe for disaster.” As of January 2026, the American Academy of Ophthalmology states plainly that it does not recommend marijuana or other cannabis products for the treatment of glaucoma, and says the American Glaucoma Society agrees.

Different countries, one shared conclusion. None of them disputing that the pressure drop is real.

The Duration Problem

 

Now the part explaining all of it.

Glaucoma has no episodes. Pressure presses on the optic nerve continuously, including while you sleep, and treatment works only by holding it down continuously.

Picture a basement that floods whenever groundwater rises. The sump pump does not need to be powerful. It needs to run whenever the water comes up, including at three in the morning when nobody is awake to notice. A pump on a three-hour timer is not a weaker version of a working pump. It is a flooded basement with good intentions.

Cannabis is the pump on the timer. The American Academy of Ophthalmology puts it plainly: research in the 1970s and 1980s showed a measurable drop in eye pressure for three or four hours. A 2006 study put numbers on that in six people with early glaucoma or raised eye pressure without nerve damage yet. Each took four turns, one treatment per session, with neither patient nor researcher knowing which was which. Two hours after five milligrams of THC under the tongue, pressure read 23.5 millimeters of mercury against 27.3 on placebo. By the four-hour measurement it had returned to where it started.

Then comes the arithmetic nobody wants to do. To hold pressure down around the clock, the American Academy of Ophthalmology estimates you would need roughly 18 to 20 milligrams of THC, six to eight times a day, every day. Glaucoma lasts the rest of your life, so that is the rest of your life. The Brazilian Glaucoma Society ran the same sum for smoking and landed on eight to ten times daily. This is where thc for glaucoma turns from a promising idea into a scheduling problem.

But scheduling is not a treatment plan.

Nor can you fix it by taking more. Higher doses deepened the drop without extending it. Stronger, not longer.

In a California compassionate-access program, nine glaucoma patients still uncontrolled on maximum treatment added THC capsules or marijuana to their regimen. All nine showed an initial drop. Four reached the target set by their physician. Not one stayed on it. Every patient elected to stop, for various reasons, the earliest after a single month and the last by nine, and the reductions did not hold.

If you are reading this with glaucoma drops in your bathroom cabinet, the next sentence is the most important one here. Do not stop, skip or reduce your prescribed glaucoma treatment, and do not substitute cannabis for any part of it. Vision lost to glaucoma is gone permanently, and a lapse in pressure control gives no warning. You will not feel it happening.

 

Where the Research Went

 

The field did not give up. It changed the question.

Because cannabinoids barely dissolve in water, the 1980 request for local delivery proved hard to fill. The THC eye drops tested in the 1970s produced burning and irritation without lowering pressure. Better formulations exist in laboratories. Most have never been in a person.

Meanwhile a group in Vienna started asking about blood supply instead of pressure. High pressure is not the only way an optic nerve dies. Poor blood flow damages it too, part of why some patients keep losing vision with pressure well controlled.

They tested oral dronabinol, a synthetic THC, first in 24 healthy volunteers in 2020, then in 2026 in 23 patients with treated open-angle glaucoma, the most common form, average age 68. Those 23 split between two doses, eleven at 5 milligrams and twelve at 10. In the twelve on the higher dose, blood flow where the optic nerve enters the eye rose significantly against placebo for up to four hours. Eye pressure did not move at all.

Twelve people, four hours, one pilot study. The authors say so themselves, and ask for long-term work on whether any of it changes disease progression or preserves vision. Nobody has shown that it does. They are asking a better question than the one asked fifty years ago.

 

Why Glaucoma Sits on Qualifying Lists

 

So why does glaucoma appear on state medical cannabis lists, the Illinois list on this site included?

California’s Proposition 215, passed in 1996 and still on the books as Health and Safety Code section 11362.5, authorized cannabis for “cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which marijuana provides relief.” Glaucoma went into the country’s first qualifying list on the strength of those 1970s and 1980s pressure findings, before anyone had reckoned with the duration problem. Later states copied the pattern. Conditions still get added to those lists, but the entries already on them rarely get a second look.

That is how these programs were built, not a hidden endorsement and not a scandal. Glaucoma qualifying condition status tells you what a legislature approved decades ago. It does not tell you what an ophthalmologist recommends this year, and it was never designed to.

 

What the Research Does Not Say

 

It does not say cannabis protects vision. We searched the literature for a randomized trial measuring what cannabis does to visual field loss in glaucoma. As of this writing there is not one. Every randomized trial here measures pressure or blood flow over hours, never sight preserved over years, the only outcome that matters.

It does not say CBD is the gentle alternative. In that same 2006 study, 20 milligrams of CBD under the tongue did not lower pressure at any point, and 40 milligrams produced a small, temporary rise at four hours. Six patients is a pilot rather than a rule, and the animal work disagrees with itself. We sell CBD products, so you can see the incentive we have to leave this paragraph out. Nobody should assume a CBD product helps eye pressure, and the only human data points the other way.

It does not say what happens over years. No study has followed glaucoma patients on cannabis long term while tracking their optic nerves. The tolerance signals in the older work are signals, not findings.

And it does not say the original finding was wrong. The pressure drop was real then and is real now. Duration killed it, not fraud.

 

Where It Leaves You

 

If your interest in cannabis began with glaucoma, the honest answer is that continuous pressure control belongs to your prescribed treatment, and cannabis does not do that job.

That settles glaucoma. It does not settle you. Most people with a glaucoma diagnosis are past sixty and rarely arrive with one condition alone, and the chronic pain, the anxiety, the sleep that stopped working years ago are what state programs were built around. Whether cannabis medicine fits any of them belongs to a physician reading your full history, eye drops included. Our guide to qualifying diagnoses shows what qualifies where you live.

If you want a physician’s read instead of a website’s, book an online evaluation. It runs the same whether this is your first patient certification or a renewal, and part of what you are paying for is a straight answer, including when the answer is no.

Frequently Asked Questions

Can I use cannabis instead of my glaucoma drops?

 

No. Not as a replacement, not as a partial replacement, and not on the days you run out. Your drops hold pressure down across the full 24 hours. Cannabis lowers it for three or four, and no trial has shown it preserves vision. Trading one for the other swaps continuous control for a long unprotected gap you cannot feel. If cost or side effects are making your drops hard to keep up with, those barriers have real solutions, and your ophthalmologist would far rather hear it now than find the damage at your next visual field test.

 

Does cannabis lower eye pressure?

 

Yes, and this is one of the few places in cannabis medicine where the answer is that simple. Smoked cannabis produces a fall in eye pressure in roughly 60 to 65 percent of users, reproduced across inhaled, oral and under-the-tongue routes since the 1970s. The limit is time, not effect. The American Academy of Ophthalmology puts the drop at three or four hours before pressure climbs back.

 

Is glaucoma a qualifying condition for medical cannabis?

 

In many states, yes, Illinois among them. It was one of the first conditions written into a state program, back in 1996. Qualifying status is a legal category rather than a clinical recommendation, and for glaucoma the two point in different directions.

 

I have glaucoma and something else. Does that change the answer?

 

It can, and this is the question worth asking. Nothing here says cannabis is wrong for you. It says cannabis is wrong for controlling eye pressure. If you also live with chronic pain, anxiety or another listed condition, that is a separate question with its own evidence. You can start an evaluation online and put the whole picture in front of someone qualified to read it.

 

This content is for educational purposes only and is not a substitute for professional medical advice. It does not diagnose any condition or recommend any product. Never stop, reduce or change a prescribed glaucoma treatment without the physician managing your care. As of April 2026, state-licensed medical cannabis and FDA-approved marijuana products are classified Schedule III under federal law, while recreational and other non-qualifying cannabis remains Schedule I. State medical cannabis programs operate under state law. Compassionate Clinics of America connects patients with licensed physicians for evaluation and patient certification; we do not prescribe, dose, or recommend specific products.

Sources

1. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87(3):222-228. PMID 7053160.
2. Joshi N, Mariam H, Kamath A. Cannabinoids for the treatment of glaucoma: a review. Medical Cannabis and Cannabinoids. 2024;7(1):183-192. PMID 39474241.
3. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. Journal of Glaucoma. 2006;15(5):349-353. PMID 16988594.
4. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Transactions of the American Ophthalmological Society. 2002;100:215-222. PMID 12545695.
5. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Archives of Ophthalmology. 1998;116(11):1433-1437. PMID 9823341.
6. Jampel H. American Glaucoma Society position statement: marijuana and the treatment of glaucoma. Journal of Glaucoma. 2010;19(2):75-76. PMID 20160576.
7. Grossman AL, Javitt MJ, Moster SJ, Grajewski AL; Pediatric Glaucoma Subcommittee of the American Glaucoma Society. American Glaucoma Society position statement on cannabinoid use in pediatric glaucoma patients. Ophthalmology Glaucoma. 2019;2(6):365-366. PMID 32672568.
8. Daga FB, Almeida I, Prata TS, Paranhos A Jr. Marijuana for glaucoma treatment: a recipe for disaster. Arquivos Brasileiros de Oftalmologia. 2021;84(2):V-VII. PMID 33787664.
9. American Academy of Ophthalmology. Does marijuana help treat glaucoma or other eye conditions? Reviewed by Andrew G. Iwach, MD. Published January 21, 2026. https://www.aao.org/eye-health/tips-prevention/medical-marijuana-glaucoma-treament
10. Lindner T, Pai V, Janku P, et al. Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma. Acta Ophthalmologica. 2026;104(2):225-232. ClinicalTrials.gov NCT04596826. PMID 40772417.
11. Hommer N, Kallab M, Szegedi S, et al. The effect of orally administered dronabinol on optic nerve head blood flow in healthy subjects: a randomized clinical trial. Clinical Pharmacology and Therapeutics. 2020;108(1):155-161. PMID 31977076.
12. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120(10):1268-1279. PMID 12365904.
13. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. PMID 24974815.
14. California Health and Safety Code section 11362.5 (Proposition 215, 1996). https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=HSC&sectionNum=11362.5
15. Absence search (PubMed, run 2026-08-31): no randomized trial of cannabis or any cannabinoid measuring glaucoma visual-field progression.